Ultragenyx Pharmaceutical Inc (RARE)
46.00
-0.40
(-0.86%)
USD |
NASDAQ |
Nov 21, 16:00
46.00
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Gross Profit Margin (Quarterly): 84.93% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 84.93% |
June 30, 2024 | 85.53% |
March 31, 2024 | 83.89% |
December 31, 2023 | 90.54% |
September 30, 2023 | 88.79% |
June 30, 2023 | 90.85% |
March 31, 2023 | 87.80% |
December 31, 2022 | 94.85% |
September 30, 2022 | 90.48% |
June 30, 2022 | 90.74% |
March 31, 2022 | 92.37% |
December 31, 2021 | 95.79% |
September 30, 2021 | 94.89% |
June 30, 2021 | 96.39% |
Date | Value |
---|---|
March 31, 2021 | 94.78% |
December 31, 2020 | 94.01% |
September 30, 2020 | 97.12% |
June 30, 2020 | 97.08% |
March 31, 2020 | |
December 31, 2019 | 85.65% |
September 30, 2019 | 89.60% |
June 30, 2019 | 96.83% |
March 31, 2019 | 97.51% |
December 31, 2018 | 96.88% |
September 30, 2018 | 97.68% |
June 30, 2018 | 98.90% |
March 31, 2018 | 97.89% |
December 31, 2017 | 99.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
83.89%
Minimum
Mar 2024
97.12%
Maximum
Sep 2020
91.39%
Average
90.85%
Median
Jun 2023
Gross Profit Margin (Quarterly) Benchmarks
Alnylam Pharmaceuticals Inc | 82.85% |
NovaBay Pharmaceuticals Inc | 65.26% |
Palatin Technologies Inc | -- |
iBio Inc | -- |
Theriva Biologics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -226.6% |
Return on Assets | -38.86% |
Return on Invested Capital | -226.6% |
Profit Margin (Quarterly) | -95.71% |
Operating Margin (Quarterly) | -94.62% |
Return on Net Operating Assets | -89.32% |